Neurontin Ruling Is Guide For DoJ Off-Label Promotion Cases – Prosecutor
Executive Summary
A recent ruling in the Neurontin "whistleblower" case lays the groundwork for future prosecutions involving off-label promotions under the False Claims Act, Philadelphia Assistant U.S. Attorney Virginia Gibson said Oct. 2 during an audioconference sponsored by the Pharmaceutical Compliance Forum
You may also be interested in...
Off-Label Promotion Remains Vulnerable To Prosecution, DoJ Says
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation
Off-Label Promotion Remains Vulnerable To Prosecution, DoJ Says
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation
Warner-Lambert GMP Conviction Plays Role In Neurontin Case
Warner-Lambert's 1995 guilty plea related to good manufacturing practices compliance is an important factor in the Neurontin off-label promotion case settled by Pfizer on May 13